Intermittent Fasting for Women

Intermittent fasting gets marketed to women as a metabolic reset, a hormone balancer, a PCOS fix, and a menopause survival tool, sometimes all in the same Instagram caption. Almost none of that marketing distinguishes between what randomized trials show and what a wellness influencer extrapolated from a rat study. Here is what the clinical research in women specifically has found, protocol by protocol and condition by condition.

What “intermittent fasting” actually means

The research uses a handful of distinct protocols, and lumping them together is where a lot of the confusion starts.

• Time-restricted eating (TRE) or Time-restricted feeding (TRF): All calories are consumed within a window of roughly 4 to 12 hours, most commonly an 8-hour eating window and a 16-hour fasting window (8:16), with no formal calorie counting.
• Alternate-day fasting (ADF): This refers to a full or near-full fasting every other day.
• 5:2: Two non-consecutive days a week at very low calorie intake, with five days of normal eating.
• Ramadan-style dawn-to-sunset fasting: A specific, time-limited religious pattern, studied heavily but not directly generalizable to voluntary year-round fasting.

Most of the trial data in women comes from TRE. Keep that in mind, because a claim backed by a 16:8 study doesn’t automatically transfer to ADF or 5:2.

Weight loss: real, but not superior to calorie restriction

The headline finding across the strongest trials is that TRE produces meaningful weight loss, and it produces it about as well as straightforward calorie restriction, but not better.

The TREAT randomized clinical trial enrolled 116 adults with overweight or obesity in either a 16:8 TRE pattern or a consistent three-meals-a-day pattern for 12 weeks. Weight loss was small in both groups (1.17% versus 0.75%), and the difference between them was not statistically significant.¹

A 2025 systematic review and meta-analysis focused specifically on overweight and obese women found TRE beat conventional (unrestricted) diets on weight loss, but showed no advantage over calorie restriction alone.² When TRE is layered on top of an existing calorie deficit rather than compared against one, the added benefit is modest: one meta-analysis found TRE plus calorie restriction outperformed calorie restriction alone by about 2 kg of extra weight loss over study periods ranging from 8-14 weeks, alongside a small additional drop in waist circumference.³

So the honest summary for a patient is this: fasting windows are a tool for controlling total intake without having to track it, and for some patients that structure is the difference between adherence and drop-out. It is not a metabolic shortcut that bypasses energy balance.

When people eat their last meal of the day and then stop eating, what type of foods are they automatically eliminating? The simple answer: junk food. Snacking after dinner often entails high-calorie, fatty, salty, low-nutrient foods like chips and popcorn. The simple act of not eating after dinner removes a significant source of empty calories.

For TRE specifically: does the time of day matter?

Given how much of the weight-loss data above is TRE, the natural follow-up question is whether the 8 am-4 pm and 1 pm-9 pm windows are actually equivalent; the evidence suggests they are not.

The largest and most direct answer comes from a 2026 network meta-analysis in BMJ Medicine pooling 41 RCTs and 2,287 participants. It classified eating windows by both timing (early, meaning the last meal before 5 pm; mid, between 5 and 7 pm; late, after 7 pm; or self-selected) and duration (under 8 hours, exactly 8 hours, or over 8 hours). Early TRE significantly outperformed late TRE on body weight (about 1.15 kg greater reduction) and fasting insulin, with high-certainty evidence behind both findings. Eating duration mattered less consistently: shorter windows trended better for glycemic and body-composition outcomes, but the effect wasn’t as reliable as timing was.²²

A separate narrative review of chrononutrition trials in obesity reached a similar practical conclusion: 8 to 10 hour windows tend to offer the best balance of metabolic benefit and adherence, while very short windows (4 to 6 hours) show strong metabolic signals on paper but are hard to sustain, and very long windows (12 to 14 hours) barely function as TRE at all.²³

The proposed mechanism is alignment with your circadian rhythm: insulin sensitivity, glucose tolerance, and the thermic effect of food are naturally higher earlier in the day, so concentrating calories in the morning and early afternoon works with that rhythm rather than against it, and a late window pushes eating closer to the body’s overnight low insulin sensitivity period.

Two caveats are worth putting forward before you reorganize your whole schedule around a 7 am-3 pm window. First, not every trial agrees. A 2025 randomized trial in Nature Medicine that directly compared early, late, and self-selected 8-hour windows against usual care found no significant difference in visceral fat reduction among the three timing groups.²⁴

Second, a crossover trial in women specifically (the ChronoFast study, comparing an 8 am-4 pm window against a 1 pm-9 pm window) found that even though the late window did measurably shift circadian clock gene expression, it produced no significant difference in cardiometabolic outcomes compared to the early window over the two-week intervention periods.²⁵ So “early is better” is the best-supported general direction, not a guarantee that a late-window patient is doing something metabolically counterproductive.

The practical takeaway for a woman who can’t realistically stop eating at 4pm: an early-to-midday window in the 8- to 10-hour range is the best-supported default when your schedule allows it, but a consistent, sustainable window eaten at any time is going to beat an unsustainable early window that you abandon in three weeks. Consistent adherence is still doing most of the work here.²⁶

Insulin and insulin resistance: this is where IF looks genuinely useful

This is the strongest and most consistent signal in the literature, and it holds up across several independent meta-analyses.

A 2025 GRADE-assessed meta-analysis of eight RCTs in adults with metabolic syndrome found fasting significantly reduced fasting blood glucose, HbA1c, and HOMA-IR, along with LDL cholesterol and IL-6.⁴ A separate 2025 GRADE meta-analysis of ten studies (701 participants) found the same pattern: fasting blood sugar, fasting insulin, HOMA-IR, and HbA1c all improved significantly with fasting interventions compared to controls.⁵ Earlier data in patients with impaired glucose and lipid metabolism showed the same direction of effect on insulin resistance and lipids.⁶ In the women-specific TRE meta-analysis referenced above, fasting insulin dropped even where total weight loss was comparable to calorie restriction, suggesting an insulin-sensitivity effect that isn’t purely explained by weight change.²

Mechanistically, this tracks: extending the overnight fast gives beta cells and hepatic insulin signalling a longer recovery window between meals, independent of total caloric intake. For a patient whose primary problem is hyperinsulinemia rather than pure adiposity, that’s a legitimate rationale, not a marketing claim.

Metabolic syndrome and hypertension: glucose responds better than blood pressure does

Metabolic syndrome as a cluster responds to fasting protocols in largely the same direction as insulin resistance alone: improved fasting glucose, HbA1c, and lipid markers across multiple meta-analyses.^4,5,7

Blood pressure is the weaker link. In people with type 2 diabetes specifically, TRE modulated systolic blood pressure without significantly affecting diastolic blood pressure or lipid profile, according to one systematic review.⁸ Other meta-analyses comparing IF to a standard diet in T2DM found no additional blood pressure benefit over usual care once weight loss was accounted for.⁹ The practical read: blood pressure improvement with IF is probably a downstream effect of weight loss and reduced sodium/caloric load, not a fasting-specific mechanism, and it shouldn’t be sold to a hypertensive patient as a guaranteed benefit independent of how much weight she actually loses.

PCOS: the most promising subgroup, with real caveats

PCOS is where intermittent fasting has the clearest theoretical rationale, because insulin resistance is central to PCOS pathophysiology across most phenotypes, and IF’s strongest, most reproducible effect is on insulin sensitivity.

A 2025 systematic review and meta-analysis in Nutrients examined IF’s effects on anthropometrics, metabolic profile, and hormones specifically in women with PCOS and reported improvements in body weight, insulin resistance markers, and androgen profile.¹⁰ A separate meta-analysis pooling six studies and 347 women with PCOS reported similar findings on metabolic and hormonal parameters, while noting the evidence base remains small and heterogeneous.¹¹

A time-restricted 5:2 protocol with meal replacement in obese women with PCOS produced significant reductions in body weight and improved insulin sensitivity and metabolic markers, though reproductive hormone levels didn’t shift significantly in that particular trial even as some participants reported improved menstrual regularity.¹² Some trials are only lasting 8 weeks. I find that significant hormonal change often takes 6 months. So any hormonal shift from intermittent fasting may just need more time.

The caveat that gets left out of most PCOS-and-fasting content: menstrual regularity improvements in these trials are inconsistent and modest, ranging roughly 33 to 40% of participants in the studies that report it at all, and the reviews themselves flag amenorrhea and anovulation as potential risks if fasting becomes too aggressive relative to a woman’s energy needs, particularly in leaner PCOS phenotypes.¹³ This is not a reason to avoid recommending it. It is a reason to individualize by PCOS type, body composition, and baseline energy availability rather than applying a single protocol across every PCOS patient in the practice.

Prediabetes and type 2 diabetes: benefits are real but tend to be weight-loss-mediated, and they fade

In type 2 diabetes, the largest meta-analysis (a Toronto-based team out of Mount Sinai, incidentally) compared IF to a standard diet and found IF produced about 1.9 kg of additional weight loss, with similar effects on HbA1c, lipid profile, and blood pressure between groups, meaning the glycemic benefit largely tracked the weight loss rather than exceeding it.⁹

A separate systematic review of RCTs found no statistically significant difference between IF and control diets on HbA1c or fasting glucose in people with T2DM, concluding IF may have more value as a prevention strategy in prediabetes than as a superior treatment once diabetes is established.¹⁴ A 2025 review of the T2DM literature reported that IF’s metabolic benefits are consistently present during active fasting but tend to disappear after the intervention is discontinued, which is really a statement about durability of any dietary intervention rather than something specific to fasting.¹⁵

For prediabetes specifically, the insulin-sensitivity data above applies most directly, since that’s the population where preventing progression to diabetes is the actual clinical target, and where the glucose and HOMA-IR improvements seen in the metabolic syndrome meta-analyses are most relevant.

Intermittent Fasting for pre-menopausal versus post-menopausal women

This is a question worth separating into two parts, because the data says something different for each.

Weight and metabolic risk markers

A secondary analysis of an 8-week TRF (time-restricted feeding) trial directly compared premenopausal (n=13) and postmenopausal (n=19) women with obesity. Both groups lost about 3.3% of body weight, with no significant difference by menopausal status, and fasting insulin, insulin resistance, and oxidative stress markers improved similarly in both groups.¹⁶ So menopausal status doesn’t appear to blunt or enhance the core metabolic response to TRE.

Menopause Symptoms and Context

Postmenopausal women carry distinct baseline risks that change how I would counsel them about fasting, even if the metabolic mechanism is unchanged: central adiposity redistribution, elevated cardiovascular risk starting in the menopausal transition, and bone health considerations that make adequate calcium, vitamin D, and protein intake within the eating window non-negotiable.¹⁷

Interestingly, a quasi-randomized trial combining 16:8 TRE with resistance and endurance training in menopausal women found the combination group had significantly greater reductions in Menopause Rating Scale scores, including both psychological and somatic symptom domains, compared to exercise alone, though the study was small and used a quasi-random design with participant preference influencing group allocation.¹⁸ A larger four-arm RCT in women aged 40 to 60 found flexible TRE combined with aerobic exercise produced greater fat mass reduction than either intervention alone.¹⁹

For premenopausal women, the specific concern is reproductive: energy availability and GnRH pulsatility are sensitive to caloric and macronutrient timing, and aggressive fasting protocols in lean, active, or already low-energy-intake women carry a real risk of menstrual disruption that doesn’t show up the same way in postmenopausal women.²⁰

Where Intermittent Fasting can do more harm than good

The evidence-based caution list here is drawn from the same trial populations and monitoring protocols used above.

• Menstrual and reproductive disruption. The mechanism is energy availability, not fasting per se: when caloric intake within the eating window isn’t sufficient to meet energy expenditure, GnRH pulsatility and LH secretion can be suppressed, leading to missed periods, anovulation, or, in more severe cases, functional hypothalamic amenorrhea.^13,20 This risk is highest in women who are already lean, highly active, under-eating, or have a history of irregular cycles.
• Disordered eating risk. Clinical trial protocols document adverse effects including irritability, difficulty concentrating, disrupted sleep, and increased psychological stress around eating, and there’s legitimate concern in the eating disorder literature that structured fasting windows can normalize restrictive patterns in vulnerable patients.²¹
• Contraindicated populations. Pregnancy, breastfeeding, actively trying to conceive, a personal history of an eating disorder, being underweight, and unmanaged hypoglycemia risk (including insulin-treated diabetes without close monitoring) are the clear stop signs, echoed consistently across trial exclusion criteria and clinical reviews.^13,20,21
• Nutrient adequacy. Compressing intake into a shorter window makes it easier to underconsume protein, calcium, iron, and fibre, which is particularly relevant for postmenopausal bone health and for any patient already managing a restrictive diet for another reason.

None of this means intermittent fasting is unsafe as a general category. It means the same due diligence applies here as to any calorie-altering intervention: screen for eating disorder history, assess menstrual regularity and energy availability before recommending it to a premenopausal patient, and monitor rather than assume it’s benign because it’s popular online.

The bottom line about intermittent fasting

Set against the marketing and the influencers, the actual evidence is fairly modest and fairly specific. TRE produces real weight loss, roughly equivalent to calorie restriction. Its most consistent and mechanistically sound benefit is improved insulin sensitivity, which makes it a reasonable tool in insulin-resistant phenotypes of PCOS, metabolic syndrome, and prediabetes, populations where that specific mechanism is the actual target. Its blood pressure and lipid benefits appear to be downstream of weight loss rather than independent effects.

Menopausal status doesn’t seem to change the metabolic response much, but it does change the risk profile for bone and cardiovascular health, which needs to be managed alongside it. And for premenopausal women, especially those who are lean, active, or have a history of cycle irregularity, energy availability should be checked before the eating window is narrowed, not after a period is missed.

It’s a tool. It fits some patients and phenotypes better than others, and it’s no more magic and no more dangerous than any other structured approach to when and how much a person eats.

Frequently asked questions about intermittent fasting

Is intermittent fasting better than a regular calorie-restricted diet for weight loss?

Not according to the head-to-head trials. TRE produces weight loss on par with straightforward calorie restriction, not consistently more of it.^1,2 Its real advantage is that some people find a fixed eating window easier to sustain than counting calories, which matters for adherence but isn’t a separate metabolic effect.

Does intermittent fasting lower insulin and improve insulin resistance?

This is the effect with the most consistent support across multiple 2025 meta-analyses: fasting blood glucose, fasting insulin, HOMA-IR, and HbA1c all improved significantly with fasting interventions compared to controls, in some cases even when weight loss was similar between groups.^4,5,6 This is the strongest evidence-based rationale for recommending IF to a specific patient.

Can intermittent fasting help with PCOS?

The rationale is sound because insulin resistance drives much of PCOS pathophysiology, and multiple 2025 meta-analyses report improvements in insulin sensitivity, body weight, and androgen profile in women with PCOS who use IF protocols.^10,11,12 Menstrual regularity improvements are real in some trials but inconsistent, and the same reviews flag amenorrhea and anovulation as risks in lean PCOS phenotypes if the fasting protocol outpaces the woman’s actual energy needs.^11,13

Will intermittent fasting help lower blood pressure?

Only indirectly, as far as the evidence shows. Blood pressure improvements in the trials track with weight loss rather than appearing as an independent fasting effect, and diastolic pressure in particular tends not to move even when systolic pressure does.^8,9

Is intermittent fasting effective for prediabetes or type 2 diabetes?

For prediabetes, the insulin sensitivity and HOMA-IR data above are directly relevant, since preventing progression is the target in that population. For established type 2 diabetes, the picture is more modest: intermittent fasting yields additional weight loss compared to a standard diet, but improvements in HbA1c and glycemic control largely track that weight loss rather than exceed it, and some reviews report that the metabolic benefits fade once the fasting protocol is stopped.^8,9,14,15

Does it matter if I’m premenopausal or postmenopausal?

Not for the core metabolic response. A direct comparison of premenopausal and postmenopausal women following the same TRF protocol found equivalent weight loss and equivalent improvements in insulin and insulin resistance between groups.¹⁶ What differs is the surrounding context: postmenopausal women need to actively protect bone health and manage elevated cardiovascular risk within whatever eating window they choose, while premenopausal women need their energy availability checked before narrowing a window, since under-fueling relative to expenditure is the actual mechanism behind fasting-related menstrual disruption.^17,20

Can intermittent fasting hurt my hormones or my period?

It can, in a specific and identifiable way. The risk isn’t fasting itself; it’s insufficient total energy intake relative to what your body needs, which can suppress the pulsatile hormone signalling (GnRH and LH) that drives regular ovulation.^13,20 This risk concentrates in women who are already lean, highly active, under-eating, or have a history of irregular cycles or disordered eating, which is exactly the population where intermittent fasting should be introduced cautiously or not at all.

What eating window should I actually use?

The best-supported default is an 8 to 10 hour window positioned earlier in the day rather than in the evening, based on a 2026 network meta-analysis of 41 trials showing early time-restricted eating outperformed late time-restricted eating on both weight and fasting insulin.²² That said, the evidence on timing isn’t unanimous, and a consistent window a patient will actually maintain outperforms a theoretically ideal one she abandons within a few weeks.^23,24,25

Who shouldn’t try intermittent fasting?

Pregnancy, breastfeeding, actively trying to conceive, a personal history of an eating disorder, being underweight, and insulin-treated diabetes without close glucose monitoring are the clear stop signs across trial exclusion criteria and clinical reviews.^13,20,21

---

References

1. Lowe DA, Wu N, Rohdin-Bibby L, Moore AH, Kelly N, Liu YE, Philip E, Vittinghoff E, Heymsfield SB, Olgin JE, Shepherd JA, Weiss EJ. Effects of Time-Restricted Eating on Weight Loss and Other Metabolic Parameters in Women and Men With Overweight and Obesity: The TREAT Randomized Clinical Trial. JAMA Intern Med. 2020 Nov 1;180(11):1491-1499. doi: 10.1001/jamainternmed.2020.4153. Erratum in: JAMA Intern Med. 2020 Nov 1;180(11):1555. doi: 10.1001/jamainternmed.2020.6728. Erratum in: JAMA Intern Med. 2021 Jun 1;181(6):883. doi: 10.1001/jamainternmed.2020.8941. PMID: 32986097; PMCID: PMC7522780.
2. Chen S, Zhang X, Kortas J, Liu H. Effects of time-restricted eating on body composition and metabolic parameters in overweight and obese women: a systematic review and meta-analysis. Front Nutr. 2025 Sep 16;12:1664412. doi: 10.3389/fnut.2025.1664412. PMID: 41036194; PMCID: PMC12479299.
3. Črešnovar T, Habe B, Jenko Pražnikar Z, Petelin A. Effectiveness of Time-Restricted Eating with Caloric Restriction vs. Caloric Restriction for Weight Loss and Health: Meta-Analysis. Nutrients. 2023 Nov 24;15(23):4911. doi: 10.3390/nu15234911. PMID: 38068769; PMCID: PMC10708501.
4. Lu L, Chen X, Liou S, Weng X. The effect of intermittent fasting on insulin resistance, lipid profile, and inflammation in metabolic syndrome: a GRADE-assessed systematic review and meta-analysis. J Health Popul Nutr. 2025 Aug 18;44(1):293. doi: 10.1186/s41043-025-01039-2. PMID: 40826125; PMCID: PMC12363089.
5. Song Q, Almutairi ASH, Almutairi MFA, Jamilian P, Abu-Zaid A. Intermittent fasting improves metabolic outcomes in metabolic syndrome: a systematic review and meta-analysis with GRADE evaluation. Front Nutr. 2025 Dec 11;12:1664811. doi: 10.3389/fnut.2025.1664811. PMID: 41459076; PMCID: PMC12738305.
6. Yuan X, Wang J, Yang S, Gao M, Cao L, Li X, Hong D, Tian S, Sun C. Effect of Intermittent Fasting Diet on Glucose and Lipid Metabolism and Insulin Resistance in Patients with Impaired Glucose and Lipid Metabolism: A Systematic Review and Meta-Analysis. Int J Endocrinol. 2022 Mar 24;2022:6999907. doi: 10.1155/2022/6999907. PMID: 35371260; PMCID: PMC8970877.
7. Zhang S, Sun B, Sun L, Zou S, Chen Q. Effect of intermittent fasting on obesity and metabolic indices in patients with metabolic syndrome: a systematic review and meta-analysis. BMC Endocr Disord. 2025 May 14;25(1):130. doi: 10.1186/s12902-025-01952-x. PMID: 40369509; PMCID: PMC12076832.
8. Liu F, Zhang Z, Sun W, Li T. The metabolic effects of intermittent fasting in patients with type 2 diabetes exist in the short term but disappear after its discontinuation: A systematic review and meta-analysis of randomized controlled trials. Nutr Res. 2025 Jun;138:135-150. doi: 10.1016/j.nutres.2025.04.008. Epub 2025 Apr 18. PMID: 40367729.
9. Borgundvaag E, Mak J, Kramer CK. Metabolic Impact of Intermittent Fasting in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Interventional Studies. J Clin Endocrinol Metab. 2021 Mar 8;106(3):902-911. doi: 10.1210/clinem/dgaa926. PMID: 33319233.
10. Ranneh Y, Hamsho M, Shkorfu W, Terzi M, Fadel A. Effect of Intermittent Fasting on Anthropometric Measurements, Metabolic Profile, and Hormones in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. Nutrients. 2025 Jul 25;17(15):2436. doi: 10.3390/nu17152436. PMID: 40806019; PMCID: PMC12348862.
11. Sukaina, Rida & A, Fathimath & T, Ayshath & Sajjad, Ushna & Khan, Mehreen & Fatima, Kaynat & Zafar, Sidra & Manaf, Hiba & Hanon, Mays & Odeh, Khuzami. (2025). Role of Intermittent Fasting in Polycystic Ovary Syndrome (PCOS): A Systematic Review of Hormonal Balance, Weight Loss, and Menstrual Regularity. Indus Journal of Bioscience Research. 3. 369-374. 10.70749/ijbr.v3i10.2353.
12. An W, Chen F, Wang B, Zhou S, Jiang L, An B, Cui Z, Ou X, Huang W, Yan H. Effect of a 5:2 intermittent fasting diet on obese patients with polycystic ovary syndrome. Front Endocrinol (Lausanne). 2026 Mar 18;17:1758805. doi: 10.3389/fendo.2026.1758805. PMID: 41928885; PMCID: PMC13038506.
13. Waly, T.A.; Nugroho, B.S. The Analysis Study Effect of Intermittent Fasting on Female Reproductive Hormones and Menstrual Cycle: A Comprehensive Systematic Review. Int. J. Med. Sci. Health Res. 2025, 9, 29–46, https://doi.org/10.70070/mrwarz94.
14. Sharma SK, Mudgal SK, Kalra S, Gaur R, Thakur K, Agarwal R. Effect of Intermittent Fasting on Glycaemic Control in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials. touchREV Endocrinol. 2023 May;19(1):25-32. doi: 10.17925/EE.2023.19.1.25. Epub 2023 Jan 17. PMID: 37313231; PMCID: PMC10258621.
15. Dyńka D, Rodzeń Ł, Rodzeń M, Łojko D, Deptuła A, Grzywacz Ż, Kraszewski S, Bartoń K, Martin P, Deptuła AM, Berry K, Unwin D. Intermittent fasting in the treatment of type 2 diabetes. Front Nutr. 2025 Aug 18;12:1629154. doi: 10.3389/fnut.2025.1629154. PMID: 40901288; PMCID: PMC12400867.
16. Cienfuegos S, Gabel K, Kalam F, Ezpeleta M, Lin S, Varady KA. Changes in body weight and metabolic risk during time restricted feeding in premenopausal versus postmenopausal women. Exp Gerontol. 2021 Oct 15;154:111545. doi: 10.1016/j.exger.2021.111545. Epub 2021 Aug 31. PMID: 34478825; PMCID: PMC8464526.
17. Al Zunaidy NA, Al-Khalifa AS, Alhussain MH, Althwab SA, Mohammed MA, Faris ME. The effect of Ramadan intermittent fasting on anthropometric, hormonal, metabolic, inflammatory, and oxidative stress markers in pre-and post-menopausal women: a prospective cohort of Saudi women. Front Nutr. 2024 Dec 4;11:1437169. doi: 10.3389/fnut.2024.1437169. PMID: 39698238; PMCID: PMC11652164.
18. Jóźwiak B, Szulc A, Laudańska-Krzemińska I. Time-Restricted Eating Combined with Exercise Reduces Menopausal Symptoms and Improves Quality of Life More than Exercise Alone in Menopausal Women: A Quasi-Randomized Controlled Trial. Nutrients. 2025; 17(20):3274. https://doi.org/10.3390/nu17203274
19. Dai Z, Miyashita M, Poon ET, Tian XY, Yu AP, Sit CH, Wong SH. Flexible time-restricted eating combined with exercise in a free-living setting for middle-aged women with overweight/obesity: a randomized controlled trial. Nat Commun. 2025 Nov 27;16(1):10659. doi: 10.1038/s41467-025-65678-z. PMID: 41309556; PMCID: PMC12660762.
20. Cienfuegos S, Corapi S, Gabel K, Ezpeleta M, Kalam F, Lin S, Pavlou V, Varady KA. Effect of Intermittent Fasting on Reproductive Hormone Levels in Females and Males: A Review of Human Trials. Nutrients. 2022 Jun 3;14(11):2343. doi: 10.3390/nu14112343. PMID: 35684143; PMCID: PMC9182756.
21. Fanaroff AC, Coratti S, Halaby R, Sanghavi M, O’Quinn RP, Krishnan S, Glassberg H, Bajaj A, Adusumalli S, Chokshi N, Patel MS. Feasibility and outcomes from using a commitment device and text message reminders to increase adherence to time-restricted eating: A randomized trial. Am Heart J. 2023 Apr;258:85-95. doi: 10.1016/j.ahj.2022.12.010. Epub 2023 Jan 11. PMID: 36640862; PMCID: PMC11010633.
22. Chen YE, Tsai HL, Tu YK, Chen LW. Effects of timing and eating duration of time restricted eating on metabolic outcomes: systematic review and network meta-analysis. BMJ Med. 2026 Jan 21;5(1):e001071. doi: 10.1136/bmjmed-2024-001071. PMID: 41586347; PMCID: PMC12829361.
23. Silva BM, Benzoni GG, de Lima Viliod MC, Fogagnolo C, Abud GF, Ortiz GU, de Sousa Neto IV, Rossini-Venturini AC, Travieso SG, de Freitas EC. Time-Restricted Eating, Cardiometabolic Health in Obesity and The Optimal Length of the Eating Window. Curr Nutr Rep. 2026 Mar 9;15(1):22. doi: 10.1007/s13668-026-00742-8. PMID: 41801605; PMCID: PMC12971787.
24. Dote-Montero M, Clavero-Jimeno A, Merchán-Ramírez E, Oses M, Echarte J, Camacho-Cardenosa A, Concepción M, Amaro-Gahete FJ, Alcántara JMA, López-Vázquez A, Cupeiro R, Migueles JH, De-la-O A, García Pérez PV, Contreras-Bolivar V, Muñoz-Garach A, Zugasti A, Petrina E, Alvarez de Eulate N, Goñi E, Armendariz-Brugos C, González Cejudo MT, Martín-Rodríguez JL, Idoate F, Cabeza R, Carneiro-Barrera A, de Cabo R, Muñoz-Torres M, Labayen I, Ruiz JR. Effects of early, late and self-selected time-restricted eating on visceral adipose tissue and cardiometabolic health in participants with overweight or obesity: a randomized controlled trial. Nat Med. 2025 Feb;31(2):524-533. doi: 10.1038/s41591-024-03375-y. Epub 2025 Jan 7. PMID: 39775037.
25. Peters B, Schwarz J, Schuppelius B, Ottawa A, Koppold DA, Weber D, Steckhan N, Mai K, Grune T, Pfeiffer AFH, Michalsen A, Kramer A, Pivovarova-Ramich O. Intended isocaloric time-restricted eating shifts circadian clocks but does not improve cardiometabolic health in women with overweight. Sci Transl Med. 2025 Oct 29;17(822):eadv6787. doi: 10.1126/scitranslmed.adv6787. Epub 2025 Oct 29. PMID: 41160666.